Michael Ziv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael Ziv has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Roni P. Dodiuk-Gad
Department of Dermatology, Emek Medical Center, Afula, Israel
2 shared publications - Alina Markova
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
1 shared publication - Amir Bieber
Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel
1 shared publication - Daniella Kushnir-Grinbaum
Sinclair Dermatology East Melbourne Victoria Australia
1 shared publication Eran Cohen-Barak
Department of Dermatology, Emek Medical Center, Afula, Israel
1 shared publication- Gil Yosipovitch
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center University of Miami Miller School of Medicine Miami Florida USA
1 shared publication
Latest Publications
- Open Access
- 8 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1818
Pruritus and Neuropsychiatric Symptoms Among Patients with Darier Disease—An Overlooked and Interconnected Challenge
(1) Background: Darier disease (DD) is a rare autosomal dominant disorder caused by mutations in ATP2A2, a gene that encodes the sarco(endo)plasmic reticulum calcium-ATPase 2 enzyme, which disrupts calcium homeostasis in keratinocytes. Pruritus, a frequently overlooked symptom in DD, can lead to physical and emotional complications, especially in patients with DD who are genetically predisposed to psychiatric comorbidities. (2) Methods: This study aimed to analyze pruritus and other related symptoms in patients with DD and explore their correlation with neuropsychiatric conditions, psychological challenges, disease severity, and body surface area (BSA) involvement through a retrospective review of a tertiary center. (3) Results: Data from 76 patients (equal gender distribution, mean age 44 years) revealed a prevalence of pruritus of 90.8%, surpassing symptoms such as pain (34.3%) and malodor (43.4%). Burning sensations due to DD lesions were significantly correlated with the diagnosis of comorbid neuropsychiatric conditions (p = 0.047) and psychiatric medication use (p = 0.019). While pruritus correlated with disease severity and %BSA involvement, the findings were not statistically significant. Patients reporting pruritus had a significantly higher Dermatology Life Quality Index symptom score (2.4 ± 1.0), which is defined as the presence of itch, soreness, pain, or stinging, than those who did not (1.5 ± 0.6), indicating accurate symptom reporting. (4) Conclusions: In conclusion, a striking majority of patients with DD experience pruritus, with higher prevalence among those with neuropsychiatric challenges, severe Darier disease, and greater %BSA skin involvement. Clinicians should recognize pruritus as a key therapeutic target and adopt comprehensive treatment approaches that both address the neuropsychiatric comorbidities and the added psychological burden of pruritus in patients with DD.
- 8 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (6) , 1818
Open AccessPruritus and Neuropsychiatric Symptoms Among Patients with Darier Disease—An Overlooked and Interconnected Challenge
(1) Background: Darier disease (DD) is a rare autosomal dominant disorder caused by mutations in ATP2A2, a gene that encodes the sarco(endo)plasmic reticulum calcium-ATPase 2 enzyme, which disrupts calcium homeostasis in keratinocytes. Pruritus, a frequently overlooked symptom in DD, can lead to physical and emotional complications, especially in patients with DD who are genetically predisposed to psychiatric comorbidities. (2) Methods: This study aimed to analyze pruritus and other related symptoms in patients with DD and explore their correlation with neuropsychiatric conditions, psychological challenges, disease severity, and body surface area (BSA) involvement through a retrospective review of a tertiary center. (3) Results: Data from 76 patients (equal gender distribution, mean age 44 years) revealed a prevalence of pruritus of 90.8%, surpassing symptoms such as pain (34.3%) and malodor (43.4%). Burning sensations due to DD lesions were significantly correlated with the diagnosis of comorbid neuropsychiatric conditions (p = 0.047) and psychiatric medication use (p = 0.019). While pruritus correlated with disease severity and %BSA involvement, the findings were not statistically significant. Patients reporting pruritus had a significantly higher Dermatology Life Quality Index symptom score (2.4 ± 1.0), which is defined as the presence of itch, soreness, pain, or stinging, than those who did not (1.5 ± 0.6), indicating accurate symptom reporting. (4) Conclusions: In conclusion, a striking majority of patients with DD experience pruritus, with higher prevalence among those with neuropsychiatric challenges, severe Darier disease, and greater %BSA skin involvement. Clinicians should recognize pruritus as a key therapeutic target and adopt comprehensive treatment approaches that both address the neuropsychiatric comorbidities and the added psychological burden of pruritus in patients with DD.
- Open Access
- 24 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 323
A Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-cancer therapy improves outcomes for cancer patients; however, many classes of anti-cancer therapy have been implicated in the induction of bullous dermatologic adverse events (DAE), leading to reduced patient quality of life and in some cases discontinuation of life-prolonging or palliative therapy. Timely and effective management of adverse events is critical for reducing treatment interruptions and preserving an anti-tumor effect. Bullous DAE may be limited to the skin or have systemic involvement with greater risk of morbidity and mortality. We present the epidemiology, diagnosis, pathogenesis, and management of bullous DAE secondary to anti-cancer therapies to enable clinicians to optimize management for these patients.
- 24 January 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (2) , 323
Open AccessA Review of Bullous Dermatologic Adverse Events Associated with Anti-Cancer Therapy
The rapid evolution of anti-cancer therapy (including chemotherapy, targeted therapy, and immunotherapy) in recent years has led to a more favorable efficacy and safety profile for a growing cancer population, and the improvement of overall survival and reduction of morbidity for many cancers. Anti-cancer therapy improves outcomes for cancer patients; however, many classes of anti-cancer therapy have been implicated in the induction of bullous dermatologic adverse events (DAE), leading to reduced patient quality of life and in some cases discontinuation of life-prolonging or palliative therapy. Timely and effective management of adverse events is critical for reducing treatment interruptions and preserving an anti-tumor effect. Bullous DAE may be limited to the skin or have systemic involvement with greater risk of morbidity and mortality. We present the epidemiology, diagnosis, pathogenesis, and management of bullous DAE secondary to anti-cancer therapies to enable clinicians to optimize management for these patients.
- Open Access
- 1 January 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (1) , 91-93
Toxic epidermal necrolysis–like dermatomyositis associated with antimelanoma differentiation antigen 5
- 1 January 2019
- Published by Elsevier in JAAD Case Reports
- Vol. 5 (1) , 91-93
Open AccessToxic epidermal necrolysis–like dermatomyositis associated with antimelanoma differentiation antigen 5
- 29 September 2013
- Published by Springer Nature in Current Dermatology Reports
- Vol. 2 (4) , 249-257
Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women
- 29 September 2013
- Published by Springer Nature in Current Dermatology Reports
- Vol. 2 (4) , 249-257
Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women